January 20, 2012
Genzyme To Co-Promote Thyroid Cancer Product
Cambridge-based Genzyme, a Sanofi Company with operations in MetroWest, announced it will promote a California-based company's system that helps diagnose thyroid cancer.
Genzyme will market and promote Veracyte Inc.'s Afirma Thyroid FNA Analysis. The companies said Afirma can more accurately determine whether thyroid nodules are malignant or benign.
Current procedures to analyze suspicious thyroid cells produce ambiguous results in up to 30 percent of cases, which can lead to unnecessary surgeries.
Financial terms of the agreement were not disclosed.
Genzyme called the partnership a "strong fit." The company already promotes a Thyroid cancer diagnostic tool called Thyrogen, which is for patients whose diagnosis is more certain.
WBJ Web Partners
Most Recent
Most Recent
0 Comments